* SEPAL PHARMA *
2004 - IDF
Paris
www.sepalpharma.com Discovery, Drugs
Key words: Cancer, Jasmonate
Mission: to develop jasmonate derivatives as novel anticancer therapies (with its R&D laboratories in Nes Ziona, near Tel-Aviv, Israel)
Clients: Prescribers
info@sepalpharma.com
Age: 7 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up |
Managing Dir.-CEO: Revah (Frédéric) [born 1968, Ph.D., Eng. Polytechnique, also Genethon Managing Dir. (2010- ), ex-Cerep, Rhône-Poulenc Rorer]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Herzberg (Max) [born 1940, Ph.D., ex-Orgenics (founder), D-Pharm (founder)] (also, Board Chairman)
Financers (Hist.): public (17%), founders (49%) | Turnover (M€) : n.a.
Total funding (M€) : 3.8
Last funding (M€) : 3.8
Focus : Cancers
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2008 .04 | Nomination : Dr Frédéric Revah, as CEO | ORGN | [3 years] |
| 2007 .09 | Management crisis : founder and CEO, Damien Salauze, on leave (for Institut Curie) | ORG | [3 years] |
| 2005 .06 | Listing on LSE (London) : 3.8 M€ | PBO | [0 year] |
| 2004 .08 | Company founded by Damien Salauze ([Pharm.D., MBA, ex-Auriga Partners, Rhône-Poulenc Rorer, Institut Pasteur], Christian Policard [ex-Sanofi], Max Herzberg and others, in Paris, with a subsidiary in Israel and a holding in London | ORGF | [0 year] | Actualisation / Updating: 25-Feb-2010 |
|
